What's New

Last Posted: Mar 24, 2023

• Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy.
  Giovanna Garufi et al. Therapeutic advances in medical oncology 2023 1517588359221138657
• The implementation of NILS: A web-based artificial neural network decision support tool for noninvasive lymph node staging in breast cancer.
  Looket Dihge et al. Frontiers in oncology 2023 131102254
• Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer.
  Yongcheng Chen et al. Gland surgery 2023 12(2) 197-207
• Cascade Genetic Risk Education and Testing in Families With Hereditary Cancer Syndromes: A Pilot Study.
  Steven J Katz et al. JCO oncology practice 2023 OP2200677
• Concordance between 21-gene recurrence score assay and clinicopathological predictive models in early-breast cancer patients cared for at a cancer center in Colombia.
  Mauricio Luján et al. Gaceta medica de Mexico 2023 159(1) 3-9
• Are population level familial risks and germline genetics meeting each other?
  Kari Hemminki et al. Hereditary cancer in clinical practice 2023 21(1) 3
• Assessment of a Peer Physician Coaching Partnership Between a Designated Cancer Center Genetics Service and a Community Cancer Network Hospital.
  Lauren G Santos et al. JAMA network open 2023 6(3) e231723
• Association of Breast Cancer Family History With Breast Density Over Time in Korean Women.
  Thi Xuan Mai Tran et al. JAMA network open 2023 6(3) e232420
• BRCA1 and BRCA2 germline mutation analysis from a cohort of 1267 patients at high risk for breast cancer in Brazil.
  Patricia Mazzonetto et al. Breast cancer research and treatment 2023
• Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review.
  Gillian Parker et al. PloS one 2023 18(3) e0280582
• Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs.
  David C Boyd et al. Cancers 2023 15(5)
• Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.
  Tufia C Haddad et al. JAMA oncology 2023
• Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study.
  Antonio Llombart-Cussac et al. Cancers 2023 15(5)
• Impact of the 21-gene expression assay on treatment decisions and clinical outcomes in breast cancer with one to three positive lymph nodes.
  Guan-Qiao Li et al. Frontiers in endocrinology 2023 141103949
• Artificial intelligence-based model for lymph node metastases detection on whole slide images in bladder cancer: a retrospective, multicentre, diagnostic study.
  Shaoxu Wu et al. The Lancet. Oncology 2023
• A novel deep learning model for breast lesion classification using ultrasound Images: A multicenter data evaluation.
  Nasim Sirjani et al. Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) 2023 107102560
• Applications of different machine learning approaches in prediction of breast cancer diagnosis delay.
  Samira Dehdar et al. Frontiers in oncology 2023 131103369
• Atypical ATMs: Broadening the phenotypic spectrum of ATM-associated hereditary cancer.
  Nicholas A Borja et al. Frontiers in oncology 2023 131068110
• Breast Cancer Screening Utilization and Outcomes in Women With Neurofibromatosis Type 1.
  Kevin Yan et al. Clinical breast cancer 2023
• Construction of a prognostic risk assessment model for HER2 + breast cancer based on autophagy-related genes.
  Fan Wang et al. Breast cancer (Tokyo, Japan) 2023

More